{"created":"2023-06-19T07:26:23.443359+00:00","id":14835,"links":{},"metadata":{"_buckets":{"deposit":"8870994b-307d-434a-913d-1b1799cc1857"},"_deposit":{"created_by":174,"id":"14835","owners":[174],"pid":{"revision_id":0,"type":"depid","value":"14835"},"status":"published"},"_oai":{"id":"oai:gifu-pu.repo.nii.ac.jp:00014835","sets":["212:260:312"]},"author_link":["36496","36498","36504","36505","36497","36501","36499","36502","36500","36503"],"item_3_biblio_info_3":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2023-02","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"73","bibliographicPageStart":"66","bibliographicVolumeNumber":"49","bibliographic_titles":[{"bibliographic_title":"医療薬学"}]}]},"item_3_textarea_2":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_textarea_value":"Glucocorticoid-induced osteoporosis (GIO) is a serious side effect of long-term glucocorticoid (GC) administration. However, sufcient high compliance rate data for the guidelines on the management and treatment of GIO in Japan is unavailable. Additionally, GC is prescribed at many medical departments involved in outpatient care. Community phar-macists might intervene to support more appropriate pharmacotherapy to avoid GIO. This study examines the actual state and characteristics of pharmacotherapy for GIO prevention. We investigated 136 patients from the Gifu Pharma-ceutical University pharmacy that received GC treatment continuously for over three months. We obtained the age, GC dosage, and combined medications data retrospectively from the electronic drug system and assessed the fracture risk factor using a scoring system. One hundred and two patients were recommended for prophylactic pharmacotherapy based on the guidelines on the management and treatment of GIO. Nineteen patients (18.6%) did not receive this therapy. Thus, community pharmacists should consider proposing prescriptions using the guidelines and help support GIO\nprevention."}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"ステロイド性骨粗鬆症予防に対する薬物療法の実態と特徴","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"ステロイド性骨粗鬆症予防に対する薬物療法の実態と特徴"}]},"item_type_id":"3","owner":"174","path":["312"],"pubdate":{"attribute_name":"公開日","attribute_value":"2023-03-17"},"publish_date":"2023-03-17","publish_status":"0","recid":"14835","relation_version_is_last":true,"title":["ステロイド性骨粗鬆症予防に対する薬物療法の実態と特徴"],"weko_creator_id":"174","weko_shared_id":-1},"updated":"2023-06-19T07:38:54.194171+00:00"}